Zomedica Corp. (NYSEAMERICAN:ZOM - Get Free Report) Director Johnny D. Powers acquired 100,000 shares of the stock in a transaction on Monday, November 11th. The stock was bought at an average price of $0.12 per share, with a total value of $12,000.00. Following the transaction, the director now directly owns 2,425,000 shares in the company, valued at approximately $291,000. This represents a 0.00 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Zomedica Stock Up 11.9 %
Shares of ZOM stock traded up $0.01 on Tuesday, reaching $0.14. 31,662,302 shares of the stock were exchanged, compared to its average volume of 4,718,253. The company has a market cap of $134.25 million, a P/E ratio of -2.05 and a beta of 1.06. Zomedica Corp. has a one year low of $0.12 and a one year high of $0.23.
Hedge Funds Weigh In On Zomedica
A hedge fund recently raised its stake in Zomedica stock. Price T Rowe Associates Inc. MD lifted its holdings in Zomedica Corp. (NYSEAMERICAN:ZOM - Free Report) by 41.1% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 948,300 shares of the company's stock after purchasing an additional 276,100 shares during the period. Price T Rowe Associates Inc. MD owned approximately 0.10% of Zomedica worth $139,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 8.95% of the company's stock.
Analysts Set New Price Targets
Separately, Noble Financial raised shares of Zomedica to a "strong-buy" rating in a report on Monday.
View Our Latest Report on ZOM
About Zomedica
(
Get Free Report)
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system.
Read More
Before you consider Zomedica, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zomedica wasn't on the list.
While Zomedica currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
